Insulin icodec-abae

Brand names: Awiqli · Active ingredient: Insulin Icodec

In short: Awiqli is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Forms & strengthsInjection: 700 units per mL (U-700) available as a clear and colorless solution: •3 mL single-patient-use FlexTouch prefilled pen (containing 2,100 units) •1.5 mL single-patient-use FlexTouch prefilled pen (containing 1,050 units) •1 mL single-patient-use …
LabelNovo Nordisk
Label updatedApr 09, 2026

What is Insulin icodec-abae used for?

Awiqli is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Insulin icodec-abae dosage

Awiqli FlexTouch is available as a single-patient-use FlexTouch pen.

•Inject Awiqli subcutaneously once-weekly on any day of the week on the same day each week.

•The Awiqli FlexTouch pen delivers doses in 10 unit increments and can deliver up to 700 units in a single injection.

•Individualize and titrate the dose of Awiqli based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal.

•The potency of insulin analogues, including insulin icodec-abae is expressed in units. One (1) unit of insulin icodec-abae corresponds to 1 international unit of human insulin.

•Dose adjustments may be needed with changes in renal or hepatic function or during illness to minimize the risk of hypoglycemia or hyperglycemia. Due to the long half-life of Awiqli, adjustment of dose is not advised during acute illness nor if patients make short-term changes in their physical activity level or usual diet. In these situations, consider other applicable adjustments, e.g. glucose intake or changes to other glucose lowering medication .

•Always check the product label before administration .

•Inspect visually for particulate matter and discoloration. Only use Awiqli if the solution appears clear and colorless.

•Inject Awiqli subcutaneously into the thigh, upper arm, or abdomen.

•Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis .

•During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring .

•Use Awiqli FlexTouch pen with caution in patients with visual impairment that may rely on audible clicks to dial their dose.

•DO NOT administer Awiqli intramuscularly, intravenously or in an insulin infusion pump.

•DO NOT dilute or mix Awiqli with any other insulin or solution.

•DO NOT transfer Awiqli from the Awiqli FlexTouch pen into a syringe for administration .

The recommended weekly starting dose of Awiqli in insulin naïve patients is 70 units administered subcutaneously once-weekly on the same day each week.

•Administer the first dose of Awiqli on the day after the last dose of daily basal insulin.

•

Week 1 dosage: The recommended one-time starting dosage of Awiqli FlexTouch is 1.5 times the total daily basal dosage multiplied by 7 rounded to the nearest 10 units.

•

Week 2 dosage: The recommended dosage is the previous total daily basal insulin dose multiplied by 7 and then rounded to the nearest 10 units.

•See Table 1 for examples of Awiqli dosage for Week 1 and 2, when switching from daily basal insulin therapy. …

How to take Insulin icodec-abae — instructions & advice from the label

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Hypoglycemia Due to Medication Errors and Accidental Overdose

Advise patients to always check the product label before each injection to confirm they are using Awiqli and not another insulin or injectable antidiabetic medicine. Advise patients using other injectable medications for glycemic control that the dosage selection of Awiqli differs. Instruct patients to visually verify the dialed units on the dose counter of the Awiqli FlexTouch prefilled pen before each injection to avoid dosing errors .

Hypoglycemia

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Inform patients of the symptoms of hypoglycemia (e.g., impaired ability to concentrate and react). This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery . …

Warnings & precautions

Do not take this medicine if: Awiqli is contraindicated:

•During episodes of hypoglycemia .

•In patients with hypersensitivity to insulin icodec-abae or any of the excipients in Awiqli FlexTouch. Serious hypersensitivity reactions have included anaphylaxis .

Serious hypoglycemia requiring hospitalization has occurred due to accidental mix-ups between Awiqli and other insulin products or once-weekly injectable antidiabetic medicines, incorrect dose selection, and dosing frequency errors.

To avoid dosing errors when switching from daily basal insulin to Awiqli, follow the dosage recommendations in the Dosage and Administration Section (2.2). Administer Awiqli once weekly only.

Advise patients to always check the product label before each injection to confirm they are using Awiqli and not another insulin or injectable antidiabetic medicine. Prior to initiation, train patients and their caregiver(s) on how to select their weekly Awiqli dosage. Advise patients using other injectable medications for glycemic control that the dosage selection of Awiqli differs . Instruct patients to visually verify the dialed units on the dose counter of the Awiqli FlexTouch prefilled pen before each injection to avoid dosing errors. Do not dial the maximum single dose (700 units) of Awiqli unless this is the prescribed dose . Do not use a syringe to remove Awiqli from the Awiqli FlexTouch disposable insulin prefilled pen.

Monitor patients for signs and symptoms of hypoglycemia, particularly during the first several weeks after initiation or dose escalation of Awiqli. Ensure patients understand how to recognize and manage hypoglycemia .

Hypoglycemia is the most common adverse reaction associated with insulin, including Awiqli . Severe hypoglycemia can cause seizures, may be life-threatening or cause death. …

Insulin icodec-abae side effects

The following adverse reactions are also discussed elsewhere:

•Hypoglycemia Due to Medication Errors and Accidental Overdose

•Hypoglycemia

•Hypersensitivity reactions

•Hypokalemia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of Awiqli in patients with type 2 diabetes was evaluated in five clinical trials involving 1,880 adults with type 2 diabetes exposed to Awiqli, with a mean exposure duration of 26 to 52 weeks across the five trials . The type 2 diabetes population had the following characteristics: mean age was 59 years and 5% were older than 75 years, 59% were male, 71% were White, 3.6% were Black or African American, and 13% were Hispanic or Latino ethnicity. The mean BMI was 30.7 kg/m2. The mean duration of diabetes was 13 years and the mean HbA1c at baseline was 8.6%. At baseline, the mean eGFR was 86.1 mL/min/1.73 m2 and 11% of patients had an eGFR less than 60 mL/min/1.73 m2.

Common Adverse Reactions

Hypoglycemia

Hypoglycemia is the most commonly observed adverse reaction in patients treated with Awiqli . The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. …

Drug interactions

Table 3 includes clinically significant drug interactions with Awiqli.

Table 3: Clinically Significant Drug Interactions with Awiqli

Drugs That May Increase the Risk of Hypoglycemia

Drugs: | Antidiabetic agents, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT-2) inhibitors.

Intervention: | Dose reductions and increased frequency of glucose monitoring may be required when Awiqli is co-administered with these drugs.

Drugs That May Decrease the Blood Glucose Lowering Effect of Awiqli

Drugs: | Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. …

About this medicine

Insulin icodec-abae is a once-weekly basal human insulin analog for subcutaneous injection produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae followed by chemical modification. Insulin icodec-abae differs from human insulin in that the amino acid threonine in position B30 has been omitted, Tyr(A14) has been substituted with Glu and Tyr(B16) and Phe(B25) have been substituted with His. The side chain is connected to the peptide backbone via the amino group in the side chain at Lys(B29). Insulin icodec-abae has a molecular formula of C280H435N71O87S6 and a molecular weight of 6380.26 Da. It has the following structure:

Figure 1: Structural Formula of Insulin icodec-abae

Awiqli (insulin icodec-abae) injection is a sterile, clear and colorless solution available as 700 units/mL (U-700) for subcutaneous use.

Each mL contains 700 units of insulin icodec-abae and glycerin (15 mg), metacresol (1.08 mg), phenol (5.65 mg), sodium chloride (1.17 mg), zinc acetate (101 mcg), and Water for Injection.

Awiqli has a pH of approximately 7.4. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5162b93e-5775-4581-a5e9-e8783ae0acd7. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro